Allied Healthcare Prods Azioni (OTC: AHPIQ)

Ultime notizie per Allied Healthcare Prods (OTC:AHPIQ) Azioni

Allied Healthcare Products Inc manufactures a variety of respiratory products used in the healthcare industry in a wide range of hospital and alternate site settings, including sub-acute care facilities, home health care, and emergency medical care. The product line of the company includes respiratory anesthesia products, home respiratory care products, medical gas system construction products, medical gas system regulation devices, disposable oxygen, and specialty gas cylinders, portable suction equipment, trauma, and patient handling products, respiratory products, and others. The company markets its products under various brand names Timeter, Carbolime, Litholyme, Schuco, Chemetron, Oxequip, Lif-O-Gen, Gomco, and others.

ALLIED HLTHCARE PRODS INC by Allied Healthcare Products, Inc.

Allied Healthcare Products Inc

<h3>Gainers</h3>
<ul>
<li>D-MARKET Electronic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPS#NASDAQ">HEPS</a>) shares rose 43.8% to $3.16 during Friday's regular session. The company's market cap stands at $1.0 billion. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares increased by 20.58% to $2.05. The market value of their outstanding shares is at $50.0 million. </li>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) stock moved upwards by 14.84% to $0.23. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) shares moved upwards by 14.52% to $0.18. The company's market cap stands at $10.9 million. </li>
<li>Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) shares increased by 14.28% to $1.52. The market value of their outstanding shares is at $59.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) stock decreased by 9.3% to $0.49 during Friday's regular session. The company's market cap stands at $4.6 million. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) shares fell 8.44% to $5.1. The market value of their outstanding shares is at $32.8 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) shares decreased by 8.34% to $3.3. The market value of their outstanding shares is at $16.2 million. </li>
<li>Haverty Furniture Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>) shares decreased by 6.68% to $25.58. The market value of their outstanding shares is at $419.7 million. </li>
<li>Yoshitsu Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) stock declined by 6.37% to $0.5. The company's market cap stands at $21.1 million. </li>
<li>Visionary Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) shares fell 6.37% to $1.47. The company's market cap stands at $5.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DBGI

GROV

HEPS

JDZG

KXIN

TKLF

VEEE

Connexa Sports Technologies Inc. - Common Stock

YYAI

11 Consumer Discretionary Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares increased by 142.8% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares moved upwards by 49.28% to $2.06. The market value of their outstanding shares is at $351.5 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock rose 39.74% to $0.92. The company's market cap stands at $3.6 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 30.56% to $0.63. The company's market cap stands at $13.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock rose 30.46% to $1.32. The market value of their outstanding shares is at $2.6 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock rose 27.86% to $1.15. The market value of their outstanding shares is at $29.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 31.9% to $0.48 during Friday's regular session. The company's market cap stands at $16.8 million. </li>
<li>Orgenesis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares declined by 28.05% to $2.33. The market value of their outstanding shares is at $11.1 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock decreased by 16.1% to $0.78. The market value of their outstanding shares is at $5.1 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) stock declined by 12.7% to $2.27. The company's market cap stands at $17.8 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares decreased by 9.04% to $0.7. The market value of their outstanding shares is at $4.0 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 8.84% to $1.96. The company's market cap stands at $7.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFRG

CHRO

CMAX

CTCX

CYCC

MHUA

MTEM

NKGN

ORGS

QNRX

TVGN

VTAK

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) shares increased by 123.1% to $3.93 during Friday's regular session. The market value of their outstanding shares is at $2.6 million. </li>
<li>Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) stock increased by 22.41% to $2.84. The market value of their outstanding shares is at $150.9 million. </li>
<li>Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) stock moved upwards by 19.75% to $1.49. The market value of their outstanding shares is at $223.4 million. </li>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) shares moved upwards by 19.28% to $1.67. The market value of their outstanding shares is at $13.2 million. </li>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) shares increased by 18.86% to $1.26. The company's market cap stands at $56.6 million. </li>
<li>Jet AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares rose 17.23% to $0.11. The company's market cap stands at $3.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Greenwave Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) stock fell 20.0% to $0.44 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. </li>
<li>Nixxy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) stock decreased by 13.34% to $2.34. The market value of their outstanding shares is at $9.4 million. </li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) stock declined by 10.99% to $0.51. The company's market cap stands at $7.4 million. </li>
<li>Staffing 360 Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares declined by 10.35% to $2.08. The market value of their outstanding shares is at $1.8 million. </li>
<li>Air Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIRI#AMEX">AIRI</a>) shares decreased by 8.05% to $5.88. The market value of their outstanding shares is at $19.6 million. </li>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) stock fell 7.51% to $1.6. The company's market cap stands at $50.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

AIRI

BAER

EFSH

GWAV

JTAI

NIXX

NRGV

PITA

STAF

ZONE

12 Industrials Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock increased by 47.2% to $11.7 during Friday's regular session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) stock rose 20.9% to $4.28. The company's market cap stands at $121.9 million. </li>
<li>HeartCore Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) stock rose 20.2% to $1.19. The market value of their outstanding shares is at $24.8 million. </li>
<li>Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares moved upwards by 16.24% to $1.11. The market value of their outstanding shares is at $211.4 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares increased by 16.19% to $3.3. The company's market cap stands at $24.2 million. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) stock increased by 15.17% to $0.41. The market value of their outstanding shares is at $81.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cemtrex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) shares fell 23.8% to $0.31 during Friday's regular session. </li>
<li>SPI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>) stock fell 14.16% to $0.47. The company's market cap stands at $14.8 million. </li>
<li>Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) shares declined by 11.9% to $6.59. The company's market cap stands at $74.7 million. </li>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares fell 10.54% to $3.82. The market value of their outstanding shares is at $7.7 million. </li>
<li>ReAlpha Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares declined by 7.66% to $1.09. The company's market cap stands at $48.4 million. </li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) stock declined by 7.07% to $248.02. The company's market cap stands at $8.9 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

AIRE

CETX

CMTL

HTCR

PHUN

RGTI

SOBR

12 Information Technology Stocks Moving In Friday's Intraday Session

Investors with a lot of money to spend have taken a bearish stance on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with JNJ, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Johnson &amp; Johnson.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $104,000, and 7, calls, for a total amount of $338,554.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $180.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson &amp; Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson &amp; Johnson's substantial trades, within a strike price spectrum from $160.0 to $180.0 over the preceding 30 days.
<h3>Johnson &amp; Johnson Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729269040_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.63</td>
<td>$2.4</td>
<td>$2.6</td>
<td>$165.00</td>
<td>$104.0K</td>
<td>2.3K</td>
<td>481</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.1</td>
<td>$2.3</td>
<td>$3.0</td>
<td>$165.00</td>
<td>$60.0K</td>
<td>7.9K</td>
<td>0</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.05</td>
<td>$2.97</td>
<td>$2.97</td>
<td>$165.00</td>
<td>$59.4K</td>
<td>7.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.2</td>
<td>$2.85</td>
<td>$2.93</td>
<td>$165.00</td>
<td>$58.5K</td>
<td>7.9K</td>
<td>404</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.94</td>
<td>$2.9</td>
<td>$2.94</td>
<td>$165.00</td>
<td>$51.4K</td>
<td>7.9K</td>
<td>855</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
After a thorough review of the options trading surrounding Johnson &amp; Johnson, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Johnson &amp; Johnson</h3>
<ul>
<li>Currently trading with a volume of 1,877,656, the JNJ's price is up by 0.27%, now at $164.92. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 95 days.</li>
</ul>
<h3>What The Experts Say On Johnson &amp; Johnson</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $201.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Johnson &amp; Johnson with a target price of $175. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $215. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Johnson &amp; Johnson, maintaining a target price of $185. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson &amp; Johnson options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Johnson & Johnson Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OXY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Occidental Petroleum.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 70%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $1,274,147, and 12 are calls, for a total amount of $1,230,220.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $67.5 for Occidental Petroleum during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Occidental Petroleum stands at 4763.57, with a total volume reaching 8,472.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Occidental Petroleum, situated within the strike price corridor from $30.0 to $67.5, throughout the last 30 days.
<h3>Occidental Petroleum Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729269034_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.9</td>
<td>$6.35</td>
<td>$7.8</td>
<td>$55.00</td>
<td>$780.0K</td>
<td>5.9K</td>
<td>0</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.71</td>
<td>$1.69</td>
<td>$1.69</td>
<td>$55.00</td>
<td>$552.1K</td>
<td>15.2K</td>
<td>3.4K</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.85</td>
<td>$6.75</td>
<td>$6.85</td>
<td>$57.50</td>
<td>$205.5K</td>
<td>10.7K</td>
<td>301</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$52.50</td>
<td>$175.1K</td>
<td>1.6K</td>
<td>501</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$7.25</td>
<td>$7.15</td>
<td>$7.22</td>
<td>$45.00</td>
<td>$101.0K</td>
<td>1.0K</td>
<td>141</td>
</tr>
</tbody>
</table>

<h3>About Occidental Petroleum</h3>
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,234 thousand barrels of oil equivalent per day in 2023 at a ratio of roughly 50% oil and natural gas liquids and 50% natural gas.
<h3>Occidental Petroleum's Current Market Status</h3>
<ul>
<li>With a trading volume of 5,455,701, the price of OXY is down by 0.0%, reaching $51.72.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 25 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Occidental Petroleum</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $62.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Occidental Petroleum, which currently sits at a price target of $58. 
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on Occidental Petroleum, which currently sits at a price target of $77. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Market Perform rating for Occidental Petroleum, targeting a price of $65. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Occidental Petroleum with a target price of $56. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Occidental Petroleum, targeting a price of $56. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Occidental Petroleum, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Occidental Petroleum's Options: A Look at What the Big Money is Thinking

Deep-pocketed investors have adopted a bearish approach towards Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BKNG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Booking Holdings. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 31% leaning bullish and 45% bearish. Among these notable options, 4 are puts, totaling $168,460, and 18 are calls, amounting to $1,466,141.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $3500.0 to $4550.0 for Booking Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Booking Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Booking Holdings's substantial trades, within a strike price spectrum from $3500.0 to $4550.0 over the preceding 30 days.
<h3>Booking Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729269029_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$1162.7</td>
<td>$1123.4</td>
<td>$1142.8</td>
<td>$3970.00</td>
<td>$342.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$760.7</td>
<td>$745.1</td>
<td>$758.8</td>
<td>$3600.00</td>
<td>$226.2K</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$415.8</td>
<td>$401.3</td>
<td>$415.8</td>
<td>$4000.00</td>
<td>$123.3K</td>
<td style="text-align: right;">46</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$369.0</td>
<td>$360.0</td>
<td>$360.0</td>
<td>$4000.00</td>
<td>$108.0K</td>
<td style="text-align: right;">134</td>
<td style="text-align: right;">11</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$860.0</td>
<td>$851.2</td>
<td>$860.0</td>
<td>$3500.00</td>
<td>$86.0K</td>
<td style="text-align: right;">45</td>
<td style="text-align: right;">3</td>
</tr>
</tbody>
</table>

<h3>About Booking Holdings</h3>
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Following our analysis of the options activities associated with Booking Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is Booking Holdings Standing Right Now?</h3>
<ul>
<li>With a volume of 52,189, the price of BKNG is down -0.51% at $4348.34. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
<h3>What The Experts Say On Booking Holdings</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $4170.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Booking Holdings, targeting a price of $4500. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Booking Holdings, which currently sits at a price target of $4173. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $3590. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $3590. 
&#x2A; An analyst from JMP Securities persists with their Market Outperform rating on Booking Holdings, maintaining a target price of $5000. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Booking Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

BKNG

Booking Holdings Unusual Options Activity

WIIM

Bullfrog AI shares are trading lower after the company announced a $3.13 million registered direct offering of 1.565 million shares priced at $2.00 per share.

CIBC analyst Dennis Fong maintains Vermilion Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/VET#TSX">VET</a>) with a Neutral and lowers the price target from C$22 to C$17.

News

Price Target

Analyst Ratings

TSX:VET

CIBC Maintains Neutral on Vermilion Energy, Lowers Price Target to C$17

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 100 points on Friday.
The Dow traded up 0.03% to 43,252.87 while the NASDAQ rose 0.55% to 18,474.05. The S&amp;P 500 also rose, gaining, 0.33% to 5,861.03.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Communication services shares jumped by 1.2% on Friday.
In trading on Friday, energy shares fell by 1%.
Top Headline
American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) shares fell around 5% on Friday after the company reported results for the third quarter.
The company said quarterly revenue (net of interest expense) grew 8% year-on-year to $16.64 billion, marginally missing the analyst consensus estimate of $16.67 billion. Adjusted EPS of $3.49 beat the analyst consensus estimate of $3.28.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>United States Cellular Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) shares shot up 12% to $65.62 after the company announced the sale of a portion of its retained spectrum licenses to Verizon for $1 billion.</li>
<li>Shares of Bright Minds Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) got a boost, surging 196% to $64.35. The company announced a $35 million non-brokered private placement.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares were also up, gaining 55% to $12.30 after the company announced it filed a form RW and will not pursue a public offering at this time.</li>
</ul>
<h3 class="wp-block-heading">Equities Trading DOWN</h3>
<ul>
<li>MGP Ingredients, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) shares dropped 26% to $60.24 after the company issued soft preliminary guidance and lowered its 2024 financial outlook.</li>
<li>Shares of Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) were down 11% to $0.5101. On Thursday, Canaccord Genuity downgraded the stock from Buy to Hold and cut its price target from $1.85 to $0.70.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) was down, falling 8% to $58.77 after the company cut its third-quarter outlook.</li>
</ul>
Commodities In commodity news, oil traded down 1.2% to $69.84 while gold traded up 0.9% at $2,731.90.
Silver traded up 2.9% to $32.705 on Friday, while copper rose 1.2% to $4.3785.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.1%, Germany's DAX rose 0.31% and France's CAC 40 climbed 0.35%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 fell 0.52%.
Construction output in the Eurozone fell by 2.5% year-over-year in August compared to a revised 2.3% decline in the previous month. The current account surplus in the Eurozone increased to €35.2 billion in August from €26.8 billion in the year-ago period.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index climbing 3.61%, China's Shanghai Composite Index gaining 2.91% and India's BSE Sensex gaining 0.27%.
Economics
<ul>
<li>U.S. housing starts fell by 0.5% from the previous month to an annualized rate of 1.354 million units in September.</li>
<li>Building permits declined by 2.9% to an annual rate of 1.428 million in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Trading Ideas

DRUG

LILM

MGPI

Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock&#39;s price, but are they really important?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let&#39;s see what these Wall Street heavyweights think about Agnico Eagle Mines (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aem#NYSE">AEM</a>).
Agnico currently has an average brokerage recommendation of 1.33, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 15 brokerage firms. An ABR of 1.33 approximates between Strong Buy and Buy.
Of the 15 recommendations that derive the current ABR, 11 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 73.3% and 20% of all recommendations.
<h2>Brokerage Recommendation Trends for AEM</h2>
<img alt="Broker Rating Breakdown Chart for AEM" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/AEM_10182024.png" style="width:100%" title="" /> 
The ABR suggests buying Agnico, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every &quot;Strong Sell&quot; recommendation, brokerage firms assign five &quot;Strong Buy&quot; recommendations.
In other words, their interests aren&#39;t always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock&#39;s price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock&#39;s price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
<h2>Zacks Rank Should Not Be Confused With ABR</h2>
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers&#39; vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company&#39;s changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
<h2>Is AEM Worth Investing In?</h2>
Looking at the earnings estimate revisions for Agnico, the Zacks Consensus Estimate for the current year has increased 4.1% over the past month to $3.88.
Analysts&#39; growing optimism over the company&#39;s earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Agnico.
Therefore, the Buy-equivalent ABR for Agnico may serve as a useful guide for investors.
<a href="https://www.zacks.com/stock/news/2353028/is-it-worth-investing-in-agnico-aem-based-on-wall-street-s-bullish-views?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2353028">To read this article on Zacks.com click here.</a>

Large Cap

Is It Worth Investing in Agnico Based on Wall Street's Bullish Views?

Marsh &amp; McLennan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) reported better-than-expected third-quarter <a href="https://www.benzinga.com/quote/MMC/earnings">earnings on Thursday</a>.
Marsh &amp; McLennan reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.57 per share. The company reported quarterly sales of $5.70 billion which met the analyst consensus estimate.
John Doyle, President and CEO, said: &#8220;This was a milestone quarter for Marsh McLennan as we delivered strong results and announced the acquisition of McGriff Insurance Services. Our performance demonstrated continued momentum, with 5% underlying revenue growth, 110 basis points of margin expansion and adjusted EPS growth of 4%, or 11% excluding a one-time tax benefit a year ago. We remain on track for another great year in 2024.&#8221;
M&amp;T Bank shares fell 0.4% to trade at $198.04 on Friday.
These analysts made changes to their price targets on M&amp;T Bank following earnings announcement.
<ul>
<li>RBC Capital analyst Scott Heleniak maintained Marsh &amp; McLennan with a Sector Perform and raised the price target from $232 to $242.</li>
<li>Roth MKM analyst Harry Fong maintained Marsh &amp; McLennan with a Neutral and raised the price target from $220 to $230.</li>
</ul>
Considering buying MMC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18122114/image-170-1024x490.png" alt="" class="wp-image-603119" style="width:669px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18122114/image-170-1024x490.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18122114/image-170-300x144.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18122114/image-170-768x368.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18122114/image-170.png 1357w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

These Analysts Boost Their Forecasts On Marsh & McLennan Following Upbeat Earnings

Most investors dismiss insurance stocks as the boring niche in the finance sector without realizing that this industry could significantly outperform all others during an economy ridden by threats of prolonged higher inflation. Today&#39;s environment is ripe for insurance businesses to rally further into the year, if not continue their bullish momentum into 2025.
Markets don&#39;t need to understand the insurance ins and outs to know that when the price of the assets being insured increases, so do the insurance premiums being charged to protect that item. Not only that, insurance companies will increase prices by a set premium to avoid any further inflation shocks that may come their way, making them the perfect business to keep in mind during interest rate cut cycles such as today.
The prime target, who holds significant market share and is a household name, has become the Progressive Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pgr#NYSE">PGR</a>), especially after the company reported its latest set of quarterly earnings to show investors just how much growth awaits them by choosing to invest in insurance companies this cycle. Wall Street analysts agree, and markets love it just as much.
<h2>Progressive Stock Earnings Signal Strong Growth</h2>
With inflation up roughly 3% to 3.5% over the past 12 months, Progressive&#39;s new signed-up policies had a compound effect on the company&#39;s revenues. According to the latest quarterly earnings press release, Progressive reported up to 25% jumps in net premiums written.
The addition of new premiums through policies ended up raising Progressive&#39;s premiums by 23%, laying the foundation for further double-digit growth in the rest of the business. The bottom line, exciting to investors, saw enough growth to get Wall Street&#39;s attention this quarter.
A 108% expansion in net income should be enough to send any stock into a new rally. Progressive stock&#39;s price action shows the company now trading at 96% of its 52-week high as a sign of bullish interest surrounding the stock today. But it doesn&#39;t stop there.
Earnings per share (EPS) forecasts from Wall Street analysts today are set for a flattish pattern in the next 12 months, which is considerably below the recent track record Progressive has shown markets. Over the past 12 months, Progressive reported EPS growth of up to 110% to reach $3.97.
All of this growth might not be priced in, despite the stock trading near a 52-week high price, and that is something a few Wall Street analysts &ndash; alongside broader markets &ndash; have started to notice in the way they&#39;ve expressed their views and action toward Progressive stock lately.
<h2>Wall Street Weighs In on Progressive Stock&#39;s Future: Key Insights for Investors</h2>
Now, for another gauge, investors can consider moving forward in their hunt for upside in the insurance industry; here is what Wall Street has to say about Progressive stock. This is a particularly important view now that the company has reported such a strong quarterly trend.
The consensus price target for Progressive stock is $268.2 a share today, which calls for up to 5% upside from where it trades today. While this benchmark is good enough to beat inflation this year, that&#39;s not why investors want to stick around for this insurance play.
After the company released its latest quarter, filled with double&mdash;and even triple-digit growth, analysts at Bank of America reiterated their Buy target for Progressive, this time coupling their view with a much higher price target. These analysts see the stock trading as high as $331 a share, daring it to rally by as much as 30% from where it trades today, not to mention a new all-time high for the company.
Broader markets are also willing to express their bullish view for Progressive stock today, a trend investors can see in the premiums paid for the stock compared to peers in the industry. Progressive&#39;s price-to-book (P/B) ratio of 7.5x today commands a significant premium over the insurance industry&#39;s average 2.2x valuation.
More than that, on a price-to-earnings (P/E) basis, Progressive stock again commands a premium as it trades at 21.7x compared to the industry&#39;s 15.6x multiple. Markets will typically overpay for stocks they believe will grow at above-average rates, so this time, the premium is more than justified in Progressive&#39;s triple-digit EPS growth during the year.
Lastly, there are even signs of bearish capitulation, judging by the 8% decline in short interest for Progressive over the past month, an accelerating trend as overall short interest has declined during the third quarter of 2024.
The article &quot;<a href="https://www.marketbeat.com/originals/progressive-leads-the-way-as-analysts-bet-big-on-insurance-stocks/">Progressive Leads the Way as Analysts Bet Big on Insurance Stocks</a>&quot; first appeared on MarketBeat.

Insurance

Progressive Leads the Way as Analysts Bet Big on Insurance Stocks

Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) Thursday reported <a href="https://www.benzinga.com/news/24/10/41399062/why-intuitive-surgical-shares-are-trading-higher-by-around-7-here-are-20-stocks-moving-premarket">upbeat earnings for its third quarter</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<ul>
<li>RBC Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/606ed90d9e63ea0001ef8211/shagun-singh">analyst Shagun Singh</a> reiterated an Outperform rating, while raising the price target from $525 to $555.</li>
<li>Stifel analyst Rick Wise maintained a Buy rating, while lifting the price target from $475 to $525.</li>
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/66585980a3067c00012c48c0/david-roman">analyst David Roman</a> reaffirmed a Buy rating, while raising the price target from $583 to $604.</li>
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6010072ea6fe6f000120d9a0/anthony-elian">analyst Adam Maeder</a> maintained an Overweight rating, while lifting the price target from $495 to $538.</li>
<li>Truist Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/613f4c11b4035700018daeca/brandon-king">analyst Richard Newitter</a> reiterated a Buy rating and price target of $570.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
RBC Capital Markets: Intuitive Surgical reported its third-quarter sales 2% higher than estimates. This was driven by robust procedure volume growth and gross system placements, Singh said in a note. The company also reported a 12% earnings beat on "revenue drop-through and strong margins," he added.
Management raised the low end of their guidance for procedure volumes by 50 basis points (bps) to 16%-17%, with the upper end assuming that bariatric procedures stabilize at the current quarter's rates and that headwinds in Korea and China do not worsen, the analyst stated. Management also lowered their projection for operating expense growth by 50 bps at the midpoint, he added.
Stifel: Intuitive Surgical achieved "one of the fastest installed base growth rates in years, at 15.1%," Wise said. The company is well-positioned to approach 10,000 robots installed by the end of 2024.
The midpoint of the new guidance range implies around 2.6 million procedures in 2024, the analyst stated. "Just seven months following the US da Vinci 5 (dv5) approval, Intuitive is already generating meaningful post-launch growth momentum," which suggests the potential for acceleration in 2025, he further wrote.
Goldman Sachs: Intuitive Surgical reported third-quarter revenues of $2.04 billion. That&#8217;s up 17% year-on-year and ahead of consensus of $2 billion. "Against strong YTD performance, 3Q results underscore sustained momentum in the top-line and, as importantly, the significant earnings leverage and upside in the model," Roman said
The company has "multiple layers of growth," including the continued rollout of dv5 until mid-2025, uptake of the new SP platform and continued adoption of the ION diagnostics system, the analyst stated. "Importantly, with Intuitive's consistent investment in the robotic surgery ecosystem and differentiated technology, we are increasingly confident in the company further extending its competitive advantage," he further wrote.
Piper Sandler: &#8220;We were also encouraged to see another strong placement quarter for DV5 (110 systems in Q3) and hear that ISRG is tracking towards a broad launch in mid-2025," Maeder wrote in a note. Management indicated that physician feedback of the system had been strong, he added.
Leverage was another "bright spot in the quarter," as the company reported adjusted operating margins of 37.0%, well ahead of "our 33.3% bogey," the analyst stated. Although estimates have been raised, there is "ample opportunity for upside to play out going forward," he further wrote.
Truist Securities: Intuitive Surgical delivered a massive beat on DV5, at 110 versus analyst estimate of 78, Newitter said. The upside delivered by DV5 in its soft launch is "particularly encouraging." It gives greater confidence in further estimate upside and growth acceleration into 2025, when the full launch in planned, he added.
Intuitive Surgical should be able to sustain its "already substantial lead" in a large and underpenetrated robotic opportunity.
ISRG Price Action: Shares of Intuitive Surgical had risen by 8.63% to $514.59 at the time of publication on Friday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41404035/autoliv-posts-strong-sales-joins-united-states-cellular-netflix-intuitive-surgical-and-other-big-sto">Autoliv Joins United States Cellular, Netflix, Intuitive Surgical And Other Big Stocks Moving Higher On Friday</a></li>
</ul>
Courtesy of Intuitive Surgical

Analyst Color

Earnings Beats

Reiteration

ISRG

Intuitive Surgical Posts Q3 Earnings Beat, These Analysts Raise Forecasts On DV5 Uptake

CIBC analyst Mark Jarvi maintains TransAlta (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TA#TSX">TA</a>) with a Outperformer and raises the price target from C$16 to C$16.5.

TSX:TA

CIBC Maintains Outperformer on TransAlta, Raises Price Target to C$16.5

RBC Capital analyst Matthew McKellar upgrades Clearwater Paper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) from Sector Perform to Outperform and lowers the price target from $48 to $37.

Upgrades

RBC Capital Upgrades Clearwater Paper to Outperform, Lowers Price Target to $37

Roth MKM analyst Matt Koranda maintains Byrna Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) with a Buy and raises the price target from $17 to $20.

BYRN

Roth MKM Maintains Buy on Byrna Technologies, Raises Price Target to $20

Cantourage Group SE reported its financial results for the period from July 1 to September 30 revealing a new record quarter in the company's history. The Berlin-headquartered cannabis company posted revenue of EUR 13.2 million ($14.32 million).
Last month, the company announced that it had <a href="https://www.benzinga.com/markets/cannabis/24/09/40783859/european-cannabis-producer-cantourage-reports-62-revenue-increase-projects-positive-ebitda">exceeded its total annual revenue for 2023</a> (EUR 23.6 million) from Jan.1 to August 30, 2024, by posting revenue of EUR 24.9 million. Another positive EBITDA, between EUR 900,000 and EUR 1.1 million in the third quarter of 2024, suggests Cantourage can convert current developments in European medical cannabis markets into sustainable, profitable growth. Revenue of at least EUR 40 million is expected for the full year of 2024.
"It is important for investors to realize that the only areas in Germany and Europe in which truly profitable and growing business models can be established and monetized are those related to medical cannabis," <a href="https://www.cantourage.com/en/blog-posts/medizinisches-cannabis-boomt-cantourage-group-se-verzeichnet-rekordquartal-in-q3-2024">stated</a> Philip Schetter, CEO of Cantourage, according to translation. "I am not aware of any German company that is growing significantly and operating profitably with seeds, cuttings and non-commercial association structures."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41382195/german-medical-marijuana-sales-to-reach-1-09b-by-2028-new-report">German Medical Marijuana Sales To Reach $1.09B By 2028, New Report</a>
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
Partial cannabis legalization <a href="https://www.benzinga.com/markets/cannabis/24/04/38023610/heres-what-you-need-to-know-about-weed-legalization-in-germany-that-just-took-effect" target="_blank" rel="noreferrer noopener">took effect in Germany on April 1</a>, allowing people over 18 to legally possess up to 25 grams of dried cannabis and cultivate up to three plants at home. One of the biggest breakthroughs under the law is that medical cannabis is essentially <a href="https://www.benzinga.com/markets/cannabis/24/07/39830117/medical-marijuana-regulated-as-ibuprofen-is-one-of-the-biggest-breakthroughs-of-germanys-cannabi" target="_blank" rel="noreferrer noopener">regulated like ibuprofen</a>.
Cannabis clubs became legal on July 1, 2024, and the first such marijuana social clubs <a href="https://www.benzinga.com/markets/cannabis/24/07/39690787/first-cannabis-club-in-germany-opens-lawmaker-says-it-will-stem-illicit-marker-cops-say-the-oppo" target="_blank" rel="noreferrer noopener">opened their doors on July 8</a> in Lower Saxony. However, across many other states, applications for cannabis cultivation associations face multiple setbacks. In August, Berlin granted its <a href="https://www.benzinga.com/markets/cannabis/24/08/40564933/berlin-grants-first-cannabis-cultivation-permission-lower-saxony-to-introduce-fines-with-hefty-p" target="_blank" rel="noreferrer noopener">first permission for cannabis cultivation</a>.
"The real legalization of recreational cannabis that contains THC, as is the case in North America, for example, is off the table here for the time being," added Schetter. "Nevertheless, medical cannabis is here to stay and will continue to grow. We are pleased that so many people in Germany have found their way to cannabis therapy in the past few months. This development will definitely continue in the future. Millions of cannabis users who have so far treated themselves for sleep disorders, pain or other widespread diseases – and have often resorted to unsafe products from the black market for this purpose – can now access safe preparations in pharmaceutical quality. We deliver these products through our flexible and efficient sourcing model, which we can and will continue to scale up in the months ahead. One thing is clear to us: regardless of what happens in the recreational market, the medical market will play the leading role in the years to come in ensuring that people in Germany and other European countries have access to safe, tested cannabis."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41384700/cannabis-earnings-update-marijuana-lenders-and-top-operator-to-report-results-heres-what-investo">Cannabis Earnings Update: Marijuana Lenders And Top Operator To Report Results, Here&#8217;s What Investors Need To Know</a></li>
</ul>
Courtesy of Africa Studio on Shutterstock

Cannabis

Germany's Medical Marijuana Market Is Booming, Says Cannabis Producer Reporting Record Quarter

When Elizabeth and her husband filed for Chapter 13 bankruptcy, they thought they were making a smart move to manage their growing debt. But fast-forward a few months and they're having serious second thoughts. Elizabeth explained during a call with Dave Ramsey, "We <a href="https://www.benzinga.com/personal-finance/24/08/40583428/you-cant-earn-your-way-out-of-stupidity-dave-ramsey-on-why-60k-earning-teachers-often-become-mil">panicked and did some stupid things</a>," and boy, has that panic come with a price –$91,000 in debt and two car payments they can barely handle.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>
It all started when Elizabeth lost her job, leaving the couple to juggle everything on one income. Trying to stay afloat, they made what she describes as "some stupid decisions" to dig deeper into debt rather than step back and assess the situation. They filed for Chapter 13 bankruptcy, which, in their words, "seemed like the only way out" at the time. However, as Elizabeth shared, they quickly realized the payment plan tied to Chapter 13 was putting a strain on their monthly income, even after she landed a better job.
See Also: <a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a>
They're working hard to turn things around – having yard sales and selling everything they can – but there's one big obstacle they can't shake: that Chapter 13 payment. It's become an unwanted guest at the table, eating up their income and standing in the way of their debt-free dreams.
"You've Got a Hornet's Nest in the Closet"
When Elizabeth <a href="https://www.benzinga.com/personal-finance/24/09/40838359/dave-ramsey-says-youre-wasting-5-000-a-year-if-you-spend-13-70-a-day-on-things-you-dont-need">called into the Ramsey Show for advice</a>, Dave Ramsey painted quite the picture for her. "Pretend like you took a baseball bat and you hit a hornet's nest and you threw the hornet's nest in a closet and closed the door," he said. If they dismiss their bankruptcy, "you're getting ready to open the door" to all the creditors they owe money to – credit cards, personal loans and those pesky car payments.
Trending: Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a>
In other words, those creditors won't be pleased. They'll come after the couple "with everything they've got." And Elizabeth knew it: "Oh Lord," she responded, immediately grasping the gravity of what that meant. Filing for Chapter 13 might have put their creditors on pause, but dismissing the case would unleash the swarm and they'd need a solid plan to deal with the fallout.
"Some Stupid Decisions" and $91,000 in Debt
Let's breakdown the numbers. Elizabeth and her husband owe $30,000 on each of their two cars and have about $25,000 in credit card debt. On top of that, there's $6,000 in personal loans hanging over their heads. The irony? According to Elizabeth, these cars aren't even worth what they owe – probably closer to $26,000 or $27,000.
Now that she's back to work and they've stabilized their income, they're ready to take control and dump their debt, but the bankruptcy payments are still choking their budget. With a combined monthly income of $5,100 after taxes, health insurance and a $1,400 rent payment, those debts feel like an anchor they just can't pull up.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
The Path Forward: Opening the Door to the Hornets
Dave's advice? If they want to voluntarily dismiss the Chapter 13 bankruptcy and avoid the hornets, they need a plan. "You've got to have a plan for taking care of every one of them if you're going to open the door," he explained. For starters, it's time to sell those cars. And the good news is, Elizabeth and her husband have been saving up from their yard sales and hustling in gazelle mode. They've got enough to cover the difference and pay off the cars.
The personal loans, according to Dave, will be the toughest to deal with because those lenders are "bottom feeders" who will come after them hard and fast. On the other hand, credit card companies are "incompetent and inefficient," giving them a bit more breathing room to set up payment plans. But once the <a href="https://www.benzinga.com/personal-finance/24/03/37588475/dave-ramsey-shares-he-went-bankrupt-and-lost-everything-years-ago-while-empathizing-with-caller-">bankruptcy protection is gone</a>, the couple must stay on top of things and negotiate with creditors to keep the swarm at bay.
Trending: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
Lesson Learned
Looking back, Elizabeth and her husband wish they hadn't panicked and rushed into bankruptcy. Now, with a clearer head and some solid advice from Dave, they're ready to <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">dig out of debt the old-fashioned way – </a>through hard work, sacrifice and patience. But one thing's certain: they won't forget Dave's warning. They'll be ready for whatever flies out when they open that door.
Read Next:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Personal Finance

'You Threw A Hornet's Nest In The Closet' — Couple Buried In $91,000 Debt Turns to Dave Ramsey After Panicking, Making Their Situation Worse

In the current session, the stock is trading at $37.62, after a 0.48% spike. Over the past month, Werner Enterprises Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) stock increased by 0.78%, and in the past year, by 1.57%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1729268146_0.png" alt="Past Year Chart" />

<h3>Comparing Werner Enterprises P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 63.97 in the Ground Transportation industry, Werner Enterprises Inc. has a lower P/E ratio of 37.82. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729268146_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

WERN

A Look Into Werner Enterprises Inc's Price Over Earnings

Healthcare bankruptcies slow after peaking in 2023: report

AHPIQ

AKUMQ

ATHXQ

CANOQ

DMTKQ

GMDAQ

HGENQ

NVTAQ

RADCQ

SDCCQ

SRNE

VRAYQ

Medical Suction Devices Market to Reach US$ 1.8 Billion by 2033

TYO:7733

Allied Healthcare Prods

Comments

Allied Healthcare Prods

Notizie

Ultime notizie per Allied Healthcare Prods (OTC:AHPIQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO